Jazz Pharmaceuticals enters exclusive licensing deal with Saniona

* Jazz Pharmaceuticals (NASDAQ:JAZZ [https://seekingalpha.com/symbol/JAZZ]) and Saniona on Wednesday announced [https://seekingalpha.com/pr/20206244-jazz-pharmaceuticals-enters-exclusive-licensing-agreement-with-saniona-to-develop-and] a global license agreement between the two companies.
* Under the deal, Jazz (NASDAQ:JAZZ [https://seekingalpha.com/symbol/JAZZ]) will obtain exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications, the companies said.
* Jazz will lead and fund all further development, regulatory submissions, and global commercialization efforts.
* Saniona to receive $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales.

MORE ON JAZZ PHARMACEUTICALS

* Jazz Pharmaceuticals plc 2025 Q2 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4809383-jazz-pharmaceuticals-plc-2025-q2-results-earnings-call-presentation]
* Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4809380-jazz-pharmaceuticals-plc-jazz-q2-2025-earnings-call-transcript]
* Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor [https://seekingalpha.com/article/4799642-jazz-pharmaceuticals-stock-big-potential-investor]
* Jazz Pharma wins FDA nod for Modeyso against rare brain tumor [https://seekingalpha.com/news/4481308-jazz-pharma-wins-fda-nod-brain-tumor-drug]
* Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance [https://seekingalpha.com/news/4479540-jazz-pharmaceuticals-projects-late-q4-zanidatamab-phase-iii-data-signals-leadership]